KR100675619B1 - Novel preparation method for preparing piperlonguminine compound having skin whitening activity - Google Patents

Novel preparation method for preparing piperlonguminine compound having skin whitening activity Download PDF

Info

Publication number
KR100675619B1
KR100675619B1 KR1020050073630A KR20050073630A KR100675619B1 KR 100675619 B1 KR100675619 B1 KR 100675619B1 KR 1020050073630 A KR1020050073630 A KR 1020050073630A KR 20050073630 A KR20050073630 A KR 20050073630A KR 100675619 B1 KR100675619 B1 KR 100675619B1
Authority
KR
South Korea
Prior art keywords
piperlonguminine
compound
ethyl
acid
piperate
Prior art date
Application number
KR1020050073630A
Other languages
Korean (ko)
Inventor
이승호
장영동
김영수
Original Assignee
영남대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 영남대학교 산학협력단 filed Critical 영남대학교 산학협력단
Priority to KR1020050073630A priority Critical patent/KR100675619B1/en
Application granted granted Critical
Publication of KR100675619B1 publication Critical patent/KR100675619B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58Radicals substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

A method for preparing a piperlonguminine compound is provided to be able to simply mass-produce the piperlonguminine compound having strong whitening activity as an alpha-melanocyte stimulating hormone inhibitor. The method comprises the steps of: (a) after treating an ethyl-4-diethylphosphono-2-butenoate with NaH, performing a modified Wittig condensation on it with a piperonal represented by the formula(2) to obtain an ethyl piperate represented by the formula(4); (b) hydrolyzing the ethyl piperate(4) with a strong base such as KOH so as to obtain a piperinic acid represented by the formula(5); and (c) reacting the piperinic acid(5) with an isobutyl amine in the presence of a boronic acid to obtain a piperlonguminine compound represented by the formula(1a).

Description

미백 활성을 갖는 피퍼롱구미닌 화합물의 신규 제조방법 {Novel preparation method for preparing piperlonguminine compound having skin whitening activity} Novel preparation method for preparing piperlonguminine compound having skin whitening activity

본 발명은 미백 활성을 갖는 피퍼롱구미닌 화합물을 대량으로 생산 가능한 신규 제조방법에 관한 것이다. The present invention relates to a novel production method capable of producing a large amount of piperlonguminine compound having a whitening activity.

상기의 피퍼롱구민은 (piperlonguminine; N-이소부틸-5-(1,3-벤조디옥솔-5-일)-2,4-펜타디엔아미드, 1a) 식물성 알칼로이드로서 필발(Piper longum Linn) 뿐만 아니라 다른 피퍼종 (Piper species), 다른 속(genus)에서도 분리가 보고된 바 있으며 [A. Chatterjee et al; Tet . Letters, p1797 (1966); O. P. Gupta, et al, Phytochemistry 11, 2646 (1972); A. Patra et al, Phytochemistry 13, p2889 (1974); V. S. Parmar et al, Phytochemistry 46, p597 (1997); J. R. Stohr, et al, J. Ethnopharm. 75, p133 (2001)], 이 식물은 "피팔리(Pippali)"로 명명되어 인도에서 민간요법인 아유르베다(Ayurveda) 요법상에서 천식 및 기관지염 치료에 효과적인 것으로 알려져 있다(K. R. Kirtikar and B. D. Basu, Indian Medicinal Plants Vol III, Basu, Allahabad, India: p2128 (1933)). The piperlongumin (piperlonguminine; N-isobutyl-5- (1,3-benzodioxol-5-yl) -2,4-pentadienamide, 1a) as a vegetable alkaloid as well as Piper longum Linn In addition, segregation has been reported in other Piper species and in other genus [A. Chatterjee et al; Tet . Letters , p 1797 (1966); OP Gupta, et al, Phytochemistry 11 , 2646 (1972); A. Patra et al, Phytochemistry 13 , p2889 (1974); VS Parmar et al, Phytochemistry 46 , p597 (1997); JR Stohr, et al, J. Ethnopharm . 75 , p133 (2001)], the plant is named "Pipali" and is known to be effective in treating asthma and bronchitis on Ayurveda therapy, a folk remedy in India (KR Kirtikar and BD Basu, Indian). Medicinal Plants Vol III, Basu, Allahabad, India: p2128 (1933)).

한편 본 발명자들은 하기 화학식 1a로 표기되는 피퍼롱구미닌(piperlonguminine)이 미백활성에 관계되는 티로시나아제의 합성을 유도하는 α-MSH을 저해함을 확인하여 본 발명자에 의해 특허출원을 한 바 있다(한국특허출원 제 10-2004-85631호)On the other hand the inventors are represented by the formula A patent application has been filed by the present inventors to confirm that piperlonguminine inhibits α-MSH, which induces the synthesis of tyrosinase related to whitening activity (Korean Patent Application No. 10-2004-85631). number)

Figure 112005044271210-pat00001
Figure 112005044271210-pat00001

필발 추출물에서 분리된 피페리딘 및 N-이소부틸-(E,E)-2,4-데카디엔아미드의 항알러지 활성(S. A. Dahanukar, et al, Ind . Drugs 19, p271 (1982)) 및 항암활성(J. W. Loder et al, Aust . J. Chem . 22, p1351 (1969))이 보고된 바가 있다.Anti-allergic activity of piperidine and N-isobutyl- (E, E) -2,4-decadienamide isolated from the essential extracts (SA Dahanukar, et al, Ind . Drugs 19 , p271 (1982)) and anticancer Activity (JW Loder et al, Aust . J. Chem . 22 , p1351 (1969)) has been reported.

피퍼롱구미닌 화합물을 제조하는 방법으로서 손쉽게 수득 가능한 천연물질인 피페린(piperine)으로부터 피페린산(piperic acid)을 이용한 제조방법이 알려진 바가 있다(A. Chatterjee and C. P. Dutta, Tetrahedron, 23, p1769 (1967); R. A. Olsen and G. O. Spessard, J. Agrc . Food Chem. 29, 942 (1982)). As a method for preparing a piperlonguminine compound, a method for producing piperic acid from piperine, a readily available natural substance, has been known (A. Chatterjee and CP Dutta, Tetrahedron , 23 , p1769). (1967); RA Olsen and GO Spessard , J. Agrc . Food Chem . 29 , 942 (1982)).

그러나 상기 문헌에 기재된 피퍼롱구미닌 제조방법은 그 출발물질인 피페린의 후추(pepper) 식물내 함량이 매우 소량(0.025 내지 6%)일 뿐만 아니라, 후추 원 료 단가가 고가이므로 산업적인 대량생산으로 적용하는데 한계가 있는 문제점이 있다 따라서, 피퍼롱구미닌 유도체를 화학적으로 합성하여 보다 간단하고도 대량생산이 가능한 제조방법들에 대한 연구개발이 지금까지 요구되어 왔다.However, the method for producing piperlonguminin described in the literature is not only a very small amount (0.025 to 6%) in the pepper (pepper) plant of the starting material, but also because the price of pepper raw material is expensive, industrial mass production Therefore, there has been a problem that there is a limit to the application, therefore, there has been a demand for research and development on production methods that are simple and mass-produced by chemically synthesizing the piperlonguminine derivatives.

지금까지 발표된 어느 문헌에도 피퍼롱구미닌(piperlonguminine) 화합물을 간단하고 효율적으로 대량 생산할 수 있는 합성 방법에 대한 어떠한 교시나 개시된 바 없다.None of the literature published so far discloses any teaching on the synthetic method for simple and efficient mass production of piperlonguminine compounds.

따라서, 이에 본 발명자들은 α-멜라노사이트 자극 호르몬 저해제로서 강력한 미백 활성을 갖는 피퍼롱구미닌 화합물을 간단하고도 대량으로 생산 가능한 신규 제조방법을 개발한 바, 본 발명을 완성하였다.Therefore, the present inventors have developed a novel manufacturing method capable of producing a simple and large-scale production of a piperungguminin compound having a strong whitening activity as an α-melanosite stimulating hormone inhibitor, thus completing the present invention.

본 발명의 목적은 α-멜라노사이트 자극 호르몬 저해제로서 강력한 미백 활성을 갖는 피퍼롱구미닌 화합물을 간단하고도 대량으로 생산 가능한 신규 제조방법을 제공하는 것이다.An object of the present invention is to provide a novel production method capable of producing a simple and large amount of a piperlonguminine compound having a strong whitening activity as an α-melanosite stimulating hormone inhibitor.

상기 목적을 달성하기 위하여, 본 발명은 에틸(E)-4-디에틸포스포노-2-부테노에이트(3)를 수소화나트륨(NaH) 등으로 염기처리한 다음 피페로날(2)을 와드워스-호너의 개량된 위티그 축합 반응시켜 에틸 피페레이트(4)를 제조하는 제 1단계; 에틸 피페레이트(4)에 KOH 등과 같은 강염기하에 가수분해시켜 피페린 산(5)을 얻는 제 2단계; 상기 2단계의 피페린산(5)을 보론산 존재하에서 이소부틸아민과 반응시킴으로서 본 발명의 피퍼롱구미닌 화합물(1a)을 수득하는 제조방법을 제공한다.In order to achieve the above object, the present invention base treatment of ethyl (E) -4-diethylphosphono-2-butenoate (3) with sodium hydride (NaH) or the like and then pipernal (2) A first step of producing ethyl piperate (4) by improved Wittig condensation reaction of Worth-Honner; A second step of hydrolyzing ethyl piperate (4) under a strong base such as KOH to obtain piperic acid (5); Provided is a process for obtaining the piperlonguminine compound (1a) of the present invention by reacting piperinic acid (5) in the second step with isobutylamine in the presence of boronic acid.

Figure 112005044271210-pat00002
Figure 112005044271210-pat00002

Figure 112005044271210-pat00003
Figure 112005044271210-pat00003

Figure 112005044271210-pat00004
Figure 112005044271210-pat00004

Figure 112005044271210-pat00005
Figure 112005044271210-pat00005

Figure 112005044271210-pat00006
Figure 112005044271210-pat00006

추가적으로, 본 발명은 알데히드(7)를 트리페닐피페로닐 포스포늄 할로겐화물(8)을 반응시켜 에틸 피페레이트(4)를 제조하는 제1단계; 에틸 피페레이트(4)에 KOH 등과 같은 강염기하에 가수분해시켜 피페린 산(5)을 얻는 제 2단계; 상기 2단계의 피페린산(5)을 이소부틸아민과 보론산을 가하여 반응시킴으로서 본 발명의 피퍼롱구미닌 화합물(1a)을 수득하는 제조방법을 제공한다.In addition, the present invention comprises the first step of reacting the aldehyde (7) with triphenylpiperonyl phosphonium halide (8) to produce ethyl piperate (4); A second step of hydrolyzing ethyl piperate (4) under a strong base such as KOH to obtain piperic acid (5); The pipelinic acid (5) of the second step is reacted by adding isobutylamine and boronic acid to provide a production method for obtaining the piperlonguminine compound (1a) of the present invention.

Figure 112005044271210-pat00007
Figure 112005044271210-pat00007

Figure 112005044271210-pat00008
Figure 112005044271210-pat00008

또한 본 발명의 또 다른 목적은 에틸 (E)-4-디에틸포스포노-2-부테노에이트(3)를 수소화나트륨(NaH) 등으로 염기 처리한 다음 알데히드(2)와 반응시켜 에틸 피페레이트(4)를 제조하는 제1단계; 상기 1단계의 에틸 피페레이트(4)에 KOH 등과 같은 강염기하에 가수분해시켜 피페린 산(5)을 얻는 제 2단계; 상기 2단계의 피페린산(5)을 보론산 존재하에서 이소부틸아민과 반응시킴으로서 본 발명의 피퍼롱구미닌 화합물(1a)을 수득하는 제조방법을 제공한다.Still another object of the present invention is to base the ethyl (E) -4-diethylphosphono-2-butenoate (3) with sodium hydride (NaH) or the like and then react with aldehyde (2) to ethyl piperate. (4) a first step of manufacturing; A second step of hydrolyzing the ethyl piperate (4) in the first step under a strong base such as KOH to obtain piperic acid (5); Provided is a process for obtaining the piperlonguminine compound (1a) of the present invention by reacting piperinic acid (5) in the second step with isobutylamine in the presence of boronic acid.

본 발명의 목적은 상기 α-멜라노사이트 자극 호르몬 저해제로서 강력한 미백 활성을 갖는 피퍼롱구미닌 화합물의 제조방법을 제공하는 것으로, 하기의 반응식들에 도시된 방법에 의해 화학적으로 합성될 수 있지만, 이들 예로만 한정되는 것은 아니다.   An object of the present invention is to provide a method for preparing a piperlonguminine compound having a strong whitening activity as the α-melanosite stimulating hormone inhibitor, although it can be chemically synthesized by the method shown in the following schemes, these It is not limited only to an example.

하기의 반응식들은 본 발명의 화합물들의 제조방법을 제조 단계별로 나타내는 것으로 본 발명의 화합물은 반응식 1 및 2의 합성과정에서 사용되는 시약, 용매 및 반응 순서를 바꾸는 등의 작은 변경으로 제조될 수 있다. 본 발명의 화합물은 반응식 1 및 2의 범주에 포함되지 않는 과정에 따라 합성되었으며, 이러한 화합물에 대한 상세한 합성 과정은 이들 각각의 실시예에 설명되어 있다.The following schemes represent the preparation steps of the compounds of the present invention in stages of preparation. The compounds of the present invention may be prepared with minor changes, such as changing the reagents, solvents, and reaction sequences used in the synthesis of Schemes 1 and 2. Compounds of the present invention were synthesized according to procedures not included in the scope of Schemes 1 and 2, and detailed synthesis procedures for these compounds are described in their respective examples.

먼저 본 발명의 반응 제 1단계는 하기한 반응식에 기재된 도식에 의하여 설명되는데,First, the reaction first step of the present invention is described by the scheme described in the following scheme,

Figure 112005044271210-pat00009
Figure 112005044271210-pat00009

먼저, 상기 제 1단계에서 구조식 (3)의 에틸 (E)-4-디에틸포스포노-2-부테노에이트 화합물은 시중 구입가능한 에틸 (E)-4-브로모-2-부테노에이트와 거의 동일 몰량의 트리에틸 포스페이트를 100 내지 150℃, 바람직하게는 120 내지 130℃에서 약 1 내지 24시간 동안, 바람직하게는 약 2 내지 4시간 동안 교반하면서 가열 반응시키고, 과량의 트리에틸포스파이트는 감압하에 제거하는 반응공정을 통하여 반응시키는 아르부조브 반응(Arbuzov reaction)을 통하여 약 90% 이상의 수율로 얻을 수 있으며;First, the ethyl (E) -4-diethylphosphono-2-butenoate compound of the formula (3) in the first step is combined with commercially available ethyl (E) -4-bromo-2-butenoate. Almost the same molar amount of triethyl phosphate is heated and reacted at 100 to 150 ° C, preferably at 120 to 130 ° C, for about 1 to 24 hours, preferably about 2 to 4 hours, and the excess of triethylphosphite It can be obtained in a yield of about 90% or more through the Arbuzov reaction to react through a reaction process to remove under reduced pressure;

이 단계에서 얻은 에틸 (E)-4-디에틸포스포노-2-부테노에이트(3)를 DMF와 같은 불활성 용매에서 수소화나트륨(NaH) 등으로 염기 처리한 다음 피페로날(2)과 0 내지 60℃, 바람직하게는 30 내지 35℃에서 반응시키는 와드워스-호너의 개량된 위티그 축합 반응(Wadsworth-Horner modified Wittig condensation reaction)을 이용함으로서 에틸 피페레이트(4)를 제조할 수 있다.Ethyl (E) -4-diethylphosphono-2-butenoate (3) obtained in this step was treated with sodium hydride (NaH) or the like in an inert solvent such as DMF, followed by piperonal (2) and 0. Ethyl piperate (4) can be prepared by using the Wadsworth-Horner modified Wittig condensation reaction which is reacted at from -60 [deg.] C., preferably from 30 to 35 [deg.] C.

상기한 바와 같은 에틸 피페레이트(4)를 제조하는 또 다른 선택적인 반응 공정으로서 하기와 같은 반응식 2의 반응공정도 수행가능한데:As another alternative reaction process for preparing ethyl piperate (4) as described above, the reaction process of Scheme 2 can also be carried out:

Figure 112005044271210-pat00010
Figure 112005044271210-pat00010

예를 들어, 알데히드(7)를 (F. Bohlmann, et. al. Ber. 89, p1276 (1956)) 트리페닐피페로닐 포스포늄 브로마이드와 같은 트리페닐피페로닐 포스포늄 할로겐화물(8)을 반응시키는 반응공정을 통해서도 에틸 피페레이트(4)를 제조할 수 있다. 트리페닐피페로닐 포스포늄 할로겐화물(8)을 NaH 등으로 처리한 다음 알데히드(7)를 가하여 100 내지 150 ℃, 바람직하게는 120 내지 130 ℃에서 약 1 내지 24시간 동안, 바람직하게는 약 2 내지 4시간 동안 교반하면서 가열반응시켜 약 90% 이상의 에틸 피페레이트(4)를 얻을 수 있다.For example, aldehyde (7) (F. Bohlmann, et. Al. Ber . 89 , p1276 (1956)) triphenylpiperonyl phosphonium halide (8), such as triphenylpiperonyl phosphonium bromide The ethyl piperate (4) can also be produced through the reaction step of reacting. Treating triphenylpiperonyl phosphonium halide (8) with NaH or the like followed by addition of aldehyde (7) at 100-150 ° C, preferably 120-130 ° C for about 1-24 hours, preferably about 2 By heating with stirring for 4 hours to about 90% or more ethyl piperate (4) can be obtained.

후속 공정으로서, 하기한 반응식 3의 반응공정을 통하여 피페린 산(5)을 얻을 수 있는데:As a subsequent process, pipelinic acid (5) can be obtained through the reaction of Scheme 3 below:

Figure 112005044271210-pat00011
Figure 112005044271210-pat00011

상기 제 1단계에서 얻은 에틸 피페레이트(4)에 메탄올성 KOH, NaOH 등과 같은 강염기를 가하고 100 내지 150℃, 바람직하게는 110 내지 120℃에서 약 1 내지 24시간 동안, 바람직하게는 약 4 내지 8시간 동안 교반하면서 가열반응시키는 가수분해 반응을 통하여 피페린 산(5)을 얻을 수 있다.To the ethyl piperate (4) obtained in the first step, a strong base such as methanolic KOH, NaOH, or the like is added, and it is preferably about 4 to 8 hours at 100 to 150 ° C, preferably 110 to 120 ° C, for about 1 to 24 hours. Pipeline acid (5) can be obtained through a hydrolysis reaction which is heated for a while with stirring.

최종 반응 공정으로서, 하기한 반응식 4 반응공정을 통하여 본 발명의 피퍼롱구미닌 화합물(1a)을 얻을 수 있는데:As a final reaction process, the piperlonguminine compound (1a) of the present invention can be obtained through the following Scheme 4 reaction process:

Figure 112005044271210-pat00012
Figure 112005044271210-pat00012

상기 반응식 3에서 얻은 피페린산(5)에 피페린산(5) 몰농도의 1 내지 2배의 이소부틸아민을 톨루엔과 같은 유기용매에 용해시킨 후 약 1/10 내지 1/5배 농도의 보론산을 가하여 딘-스타크 트랩(Dean-Stark trap)하에서 약 1 내지 24시간 동안, 바람직하게는 약 8 내지 16시간 동안 환류 반응시킨 후, 이 반응물에 헥산용매를 가하여 침전을 유도한 후에 얻어진 침전물을 정제하여 본 발명의 피퍼롱구미닌 화합물(1a)을 고수율(약 91%)로 수득할 수 있다.1 to 2 times isobutylamine of pipelinic acid (5) molar concentration in pipelinic acid (5) obtained in Scheme 3 in an organic solvent such as toluene, and then about 1/10 to 1/5 times A precipitate obtained after adding boronic acid to reflux for about 1 to 24 hours, preferably about 8 to 16 hours under a Dean-Stark trap, and then adding a hexane solvent to the reaction to induce precipitation. By purifying the piperlonguminine compound (1a) of the present invention can be obtained in high yield (about 91%).

상기 피퍼롱구미닌 화합물(1a)을 제조하는 제조방법중 핵심 단계는 제 1단계는 본 발명의 알칼로이드 화합물 피퍼롱구미닌 화합물을 선택적으로 합성할 수 있는 와드워스-호너의 개량된 위티그 반응(Wadsworth-Horner modified Wittig reaction)을 이용함을 특징으로 하며, 본 발명의 제조방법은 후추 자체의 고비용 및 그 출발물질인 후추(pepper) 식물내 매우 소량 함유된 피페린 (0.025 내지 6%) 때문에 산업적인 대량생산으로 적용하는데 한계가 있던 종래 기술상의 문제점을 해결하기 위하 여 출발물질로서 비교적 저가인 시중구입 가능한 피페로날(2)로 고가의 피페린을 대체하고, 이 피페로날 화합물을 에틸 (E)-4-디에틸 포스포노-2-부테노에이트와 반응시키거나 알데히드(7)를 트리페닐피페로닐 포스포늄 할로겐화물(8)을 반응시키는 신규 제조공정으로서 기존 제법상의 문제점을 해결한 신규 제조방법이다.The core step of the manufacturing method for preparing the piperlonguminine compound (1a) is the first step is an improved Wittig reaction of the wardworth-Honer capable of selectively synthesizing the alkaloid compound piperlonguminine compound of the present invention ( Wadsworth-Horner modified Wittig reaction), and the method of the present invention is industrial because of the high cost of pepper itself and its very small amount of piperin (0.025-6%) in the pepper plant. In order to solve the problems of the prior art, which have been limited to application in mass production, a relatively inexpensive commercially available piperonal (2) is used as a starting material, and the expensive piperine is replaced with ethyl (E As a new manufacturing process, reacting with 4-diethyl phosphono-2-butenoate or reacting aldehyde (7) with triphenylpiperonyl phosphonium halide (8). It is a new manufacturing method that solves the problem.

본 발명의 제조방법은 강력한 미백활성을 나타내어 미백제로서 그 효능이 입증된 피퍼롱구미닌 화합물을 화학적으로 합성하게 됨으로서 보다 간단하고도 대량생산이 가능한 합성 방법을 제공하는 등의 산업적으로 유용한 제조방법을 제공한다.The production method of the present invention provides a synthetic method that provides a simple and mass-produced synthetic method by chemically synthesizing the piperlonguminine compound, which shows a strong whitening activity and has proven its efficacy as a whitening agent. to provide.

상기 제조방법으로 얻어진 본 발명의 피퍼롱구미닌 화합물(1a)은 미백활성에 관계되는 티로시나아제의 합성을 유도하는 α-MSH을 저해함으로서, 강력한 미백활성을 나타내므로 미백제로서 각종 미백용 의약품, 건강 기능식품 및 화장료 조성물 등의 용도로 사용가능하다.      The piperlonguminine compound (1a) of the present invention obtained by the above production method inhibits α-MSH which induces the synthesis of tyrosinase related to the whitening activity, and thus shows a strong whitening activity. It can be used for such purposes as health functional food and cosmetic composition.

이하, 본 발명을 하기 실시예에 의거하여 좀더 상세하게 설명하고자 한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 범위가 이들 만으로 제한되는 것은 아니다.Hereinafter, the present invention will be described in more detail based on the following examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.

참고예Reference Example 1. 사용 기기  1. Device used

1-1. 분석기기1-1. Analyzer

본 실험에서 얻은 생성물의 구조 확인을 위해 사용된 기기는 하기와 같다.       The instrument used to confirm the structure of the product obtained in this experiment is as follows.

융점(mp)는 피셔-존스 융점측정기(Fischer-Jones melting points apparatus) 를 사용하였으며 보정은 하지 않았으며, 핵자기 공명 스펙트럼 (1H NMR) 13C NMR) 은 250 MHz 또는 400MHz (Bruker NMR spectrometer), 핵자기 공명 스펙트럼 (13C NMR) 은 100 MHz (Bruker NMR spectrometer)로 내부표준물질(Internal standard)로 TMS (tetramethylsilane), 용매는 CDCl3, DMSO-d6를 사용하였다. 짝지음(Coupling) 상수 ( J )는 Hz로 표시하였다. IR 은 퍼킨-엘머 분광기(Perkin-Elmer 1330 spectrophotometer)를 사용하여 측정하였다. Melting point (mp) was used with a Fischer-Jones melting point apparatus and was not calibrated. Nuclear magnetic resonance spectra ( 1 H NMR) 13 C NMR were 250 MHz or 400 MHz (Bruker NMR spectrometer). The nuclear magnetic resonance spectra ( 13 C NMR) were 100 MHz (Bruker NMR spectrometer), and TMS (tetramethylsilane) was used as an internal standard, and CDCl 3 and DMSO-d 6 were used as a solvent. Coupling constants ( J ) are expressed in Hz. IR was measured using a Perkin-Elmer 1330 spectrophotometer.

1-2. TLC 및 1-2. TLC and 관크로마토그래피Tube chromatography

TLC (Thin layer chromatography)는 E. Merck 사 제품인 실리카겔(Merck F254)을 사용하였으며 관크로마토그래피(Column chromatography)를 위해서는 실리카(Merck EM9385, 230-400 mesh)를 사용하였다. 또한, TLC 상에서 분리된 물질을 확인하기 위해서 UV 램프(파장 254 nm)를 이용하거나 아니스알데히드(Anisaldehyde), 과망간산칼륨(KMnO4) 발색 시약에 담근 후, 플레이트를 가열하여 확인하였다. Thin layer chromatography (TLC) was used as silica gel (Merck F254) manufactured by E. Merck, and silica (Merck EM9385, 230-400 mesh) was used for column chromatography. In addition, using a UV lamp (wavelength 254 nm) or soaked in anisealdehyde (Anisaldehyde), potassium permanganate (KMnO 4 ) coloring reagent to identify the material separated on TLC, the plate was confirmed by heating.

참고예Reference Example 2.  2. 에틸(E)-4-Ethyl (E) -4- 디에틸포스포노Diethylphosphono -2--2- 부테노에이트Butenoate (3) 중간체 제조 (3) intermediate production

에틸 (E)-4-브로모-2-부테노에이트(ethyl (E)-4-bromo-2-butenoate)(18.0 g, 0.10 mmol)를 트리에틸 포스파이트(triethyl phosphite; 18.2 g, 0.104 mmol)에 천 천히 적가하면서 교반하였다. 얻어진 반응물을 120-130℃에서 2시간 동안 가열 반응시켰다. 과량의 트리에틸 포스파이트는 감압하에 제거하였고 얻어진 잔사를 감압 증류하여 하기 물성치를 갖는 20.2g의 무색 액상의 에틸 (E)-4-디에틸포스포노-2-부테노에이트(3) 중간체를 제조하였다 (수율: 90%).Ethyl (E) -4-bromo-2-butenoate (18.0 g, 0.10 mmol) was added to triethyl phosphite (18.2 g, 0.104 mmol). Was slowly added dropwise thereto. The resulting reaction was heated at 120-130 ° C. for 2 hours. Excess triethyl phosphite was removed under reduced pressure and the resulting residue was distilled under reduced pressure to prepare 20.2 g of a colorless liquid ethyl (E) -4-diethylphosphono-2-butenoate (3) intermediate having the following physical properties. (Yield 90%).

비점 (bp): 109-112 ℃(0.01 mmHg, bath temp. 160 ℃);      Boiling point (bp): 109-112 ° C. (0.01 mmHg, bath temp. 160 ° C.);

IR (thin film): 1725 (C=O), 1658, 1250, 1025 (P=O), 968 cm-1. IR (thin film): 1725 (C = O), 1658, 1250, 1025 (P = O), 968 cm −1 .

1H NMR (250 MHz, CDCl3): 6.85 (dtd, J trans = 15.6, 2 J = 7.8, 3 J P-H = 7.5 Hz, H3), 5.94 (ddt, J trans = 15.6, 3 J = 1.3, 4 J P-H = 6.3 Hz, H2), 4.18 (q, J = 7.2 Hz, 4H), 4.09 (q, J = 7.1 Hz, 2H), 2.72 (ddd, 1 J P-H = 22.9, J = 8.0, 1.4 Hz, 2H), 1.30 (t, J= 7.0 Hz, 6H), 1.26 (t, J = 7.5 Hz, 3H). 1 H NMR (250 MHz, CDCl 3 ): 6.85 (dtd, J trans = 15.6, 2 J = 7.8, 3 J PH = 7.5 Hz, H3), 5.94 (ddt, J trans = 15.6, 3 J = 1.3, 4 J PH = 6.3 Hz, H2), 4.18 (q, J = 7.2 Hz, 4H), 4.09 (q, J = 7.1 Hz, 2H), 2.72 (ddd, 1 J PH = 22.9, J = 8.0, 1.4 Hz, 2H), 1.30 (t, J = 7.0 Hz, 6H), 1.26 (t, J = 7.5 Hz, 3H).

실시예Example 1.  One. 에틸피페레이트Ethyl piperate (4)의 제조 (4) manufacturing

1-1. 1-1. 와드워스Wardworth -- 호너Horner 개량된  Improved 위티그Whitig 축합 반응을Condensation reaction 이용한 제조 방법 (1) Manufacturing Method With (1)

건조 DMF 70 mL에 헥산으로 세척한 수소화나트륨(NaH) 약 0.05 mol(55% in mineral oil 2.3 g)을 질소 기체하에서 방치하였다. 이 슬러리를 0 ℃에서 자석교반기로 교반하면서 건조 DMF (10 mL)에 녹인 에틸(E)-4-디에틸포스포노-2-부테노에이트(11.2 g, 0.05 mol)를 30-35 ℃를 유지하고 필요하다면 냉각하면서 천천히 적 가하였다. 얻어진 혼합물들을 4시간 동안 교반하였다. 이 반응 혼합물에 건조 DMF (10 mL)에 녹인 0.05 mol 피페로날(piperonal; 분자량 150.13, 7.5g, Aldrich, Catalog #P4,910-4)을 천천히 20분 이상 적가하였다. 이 혼합물을 16시간 동안 실온에서 유지하고 물로 희석한 후에 에테르 50 mL로 4회 추출하였다. 얻어진 유기층은 무수 황산마그네슘(MgSO4)으로 건조하였다. 감압하에서 용매를 제거하여 조생성물을 얻고 이를 메틸렌클로라이드로 용출하여 실리카겔 컬럼크로마토그래법을 수행하였다. 초기에 얻은 분획(Rf=0.7, from CH2Cl2)을 재결정 용매(ether: hexane= 1:1)로 재결정을 수행하여 하기 물성치를 갖는 연황색 판상(platelet) 결정의 에틸 피페레이트(ethyl piperate) 10.90 g (94%)를 수득하였다.About 0.05 mol (55% in mineral oil 2.3 g) of sodium hydride (NaH) washed with hexane in 70 mL of dry DMF was left under nitrogen gas. While stirring the slurry at 0 ° C. with a magnetic stirrer, ethyl (E) -4-diethylphosphono-2-butenoate (11.2 g, 0.05 mol) dissolved in dry DMF (10 mL) was maintained at 30-35 ° C. And slowly added with cooling if necessary. The resulting mixture was stirred for 4 hours. 0.05 mol piperonal (molecular weight 150.13, 7.5 g, Aldrich, Catalog # P4,910-4) dissolved in dry DMF (10 mL) was slowly added dropwise to the reaction mixture over 20 minutes. The mixture was kept at room temperature for 16 hours, diluted with water and extracted four times with 50 mL of ether. The obtained organic layer was dried over anhydrous magnesium sulfate (MgSO 4 ). The solvent was removed under reduced pressure to obtain a crude product, which was eluted with methylene chloride and subjected to silica gel column chromatography. Ethyl piperate of light yellow platelet crystals having the following physical properties by recrystallization from an initially obtained fraction (Rf = 0.7, from CH 2 Cl 2 ) with a recrystallization solvent (ether: hexane = 1: 1). 10.90 g (94%) was obtained.

1-2. 1-2. 와드워스Wardworth -- 호너Horner 개량된  Improved 위티그Whitig 축합 반응을Condensation reaction 이용한 제조 방법(2) Manufacturing method that used (2)

건조 DMF 70mL에 헥산으로 세척한 수소화나트륨(NaH) 약 0.05 mol(55% in mineral oil 2.3g)을 질소 기체하에서 방치하였다. 이 슬러리를 0 ℃에서 자석교반기로 교반하면서 건조 DMF (10 mL)에 녹인 트리페닐피페로닐 포스포늄 브로마이드(8)(4.77 g, 0.01 mol)를 30-35 ℃를 유지하고 필요하다면 냉각하면서 천천히 적가하였다. 얻어진 혼합물들을 4시간 동안 교반하였다. 이 반응 혼합물에 건조 DMF (10 mL)에 녹인 알데히드(7)(1.28 g, 0.01 mol)를 20분에 걸처 천천히 적가하였다. 이 혼합물을 16시간 동안 실온에서 유지하고 물로 희석후에 에테르 50mL로 4회 추출하였다. 얻어진 유기층은 황산마그네슘(MgSO4)으로 건조하였다. 감압하에서 용매 를 제거하여 조생성물을 얻고 이를 메틸렌클로라이드로 용출하여 실리카겔 컬럼크로마토그래법을 수행하였다. 초기에 얻은 분획(Rf=0.7, from CH2Cl2)을 재결정 용매(ether: hexane= 1:1)로 재결정을 수행하여 하기 물성치를 갖는 연황색 판상(platelet) 결정의 에틸 피페레이트(ethyl piperate) 2.10 g(85%)을 수득하였다.About 0.05 mol (55% in mineral oil 2.3 g) of sodium hydride (NaH) washed with hexane in 70 mL of dry DMF was left under nitrogen gas. The slurry was stirred with a magnetic stirrer at 0 ° C. and triphenylpiperonyl phosphonium bromide (8) (4.77 g, 0.01 mol) dissolved in dry DMF (10 mL) was kept at 30-35 ° C. and slowly cooled if necessary. Added dropwise. The resulting mixture was stirred for 4 hours. To this reaction mixture was slowly added dropwise aldehyde (7) (1.28 g, 0.01 mol) dissolved in dry DMF (10 mL) over 20 minutes. The mixture was kept at room temperature for 16 h and diluted four times with 50 mL of ether after dilution with water. The obtained organic layer was dried over magnesium sulfate (MgSO 4). The solvent was removed under reduced pressure to obtain a crude product, which was eluted with methylene chloride and subjected to silica gel column chromatography. The initially obtained fraction (Rf = 0.7, from CH 2 Cl 2 ) was recrystallized with a recrystallization solvent (ether: hexane = 1: 1), and ethyl piperate of light yellow platelet crystals having the following physical properties. ) 2.10 g (85%) were obtained.

융점 (mp): 76-77℃;       Melting point (mp): 76-77 ° C;

1H NMR (250 MHz, CDCl3): 7.39 (dd, 1H, J = 15.3, 10.3 Hz, H3), 6.97 (d, 1H, J = 1.5 Hz, H2'), 6.89 (dd, 1H, J = 8.0, 1.5 Hz, H6'), 6.77 (dd, 1H, J = 15.0, 10.0 Hz, H4), 6.76 (d, 1H, J = 8.0 Hz, H5'), 6.70 (d, 1H, J= 10.3 Hz, H5), 5.97 (s, 2H, OCH2O), 5.92 (d, 1H, J= 15.3 Hz, H2), 4.20 (q, 2H, J = 7.1 Hz), 1.29 (t, 3H, J = 7.1 Hz); 1 H NMR (250 MHz, CDCl 3 ): 7.39 (dd, 1H, J = 15.3, 10.3 Hz, H3), 6.97 (d, 1H, J = 1.5 Hz, H2 '), 6.89 (dd, 1H, J = 8.0, 1.5 Hz, H6 '), 6.77 (dd, 1H, J = 15.0, 10.0 Hz, H4), 6.76 (d, 1H, J = 8.0 Hz, H5'), 6.70 (d, 1H, J = 10.3 Hz , H5), 5.97 (s, 2H, OCH 2 O), 5.92 (d, 1H, J = 15.3 Hz, H2), 4.20 (q, 2H, J = 7.1 Hz), 1.29 (t, 3H, J = 7.1 Hz);

13C NMR (CDCl3, 62.5 MHz) 167.17, 148.49, 148.24, 144.70, 140.07, 130.54, 124.51, 122.91, 120.41, 108.51, 105.82, 101.36, 60.27, 14.31. 13 C NMR (CDCl 3 , 62.5 MHz) 167.17, 148.49, 148.24, 144.70, 140.07, 130.54, 124.51, 122.91, 120.41, 108.51, 105.82, 101.36, 60.27, 14.31.

실시예Example 2.  2. 피페린 산 (5)의 제조Preparation of Piperinic Acid (5)

상기 실시예 1에서 얻은 에틸 피페레이트(2.46 g, 0.01 mol) 및 10% 메탄올성 KOH (100 mL) 혼합물을 110 ℃에서 6시간 동안 환류 가열하였다. 얻어진 연황색 침전물을 회수하고 증류수에 재용해하였다 (60mL). 얻어진 수용액을 6N 염산으로 산성화시켜 부유성(flocculent) 황색 침전물을 얻고 이를 메탄올로 재결정하여 정량적 수율로 하기 물성치를 갖는 연황색 침상 결정의 피페린 산(piperic acid) 2.10 g (96%)를 수득하였다. The mixture of ethyl piperate (2.46 g, 0.01 mol) and 10% methanolic KOH (100 mL) obtained in Example 1 was heated to reflux at 110 ° C. for 6 hours. The pale yellow precipitate obtained was recovered and redissolved in distilled water (60 mL). The resulting aqueous solution was acidified with 6N hydrochloric acid to give a flocculent yellow precipitate which was recrystallized from methanol to give 2.10 g (96%) of piperic acid of light yellow acicular crystals having the following physical properties in quantitative yield. .

융점 (mp): 217-218℃ (문헌치; 217-218℃)       Melting point (mp): 217-218 ° C. (literature; 217-218 ° C.)

1H NMR (250 MHz, DMSO-d6) d 7.28 (ddd, J = 15.0, 4.8, 1.2 Hz, 1H, H3), 7.22 (s, H2'), 7.01-6.89 (m, 4H), 6.03 (s, 2H, -OCH2O-), 5.91 (d, J = 15.0 Hz, H2); 1 H NMR (250 MHz, DMSO-d 6 ) d 7.28 (ddd, J = 15.0, 4.8, 1.2 Hz, 1H, H3), 7.22 (s, H2 '), 7.01-6.89 (m, 4H), 6.03 ( s, 2H, -OCH 2 0-, 5.91 (d, J = 15.0 Hz, H2);

13C NMR (62.5 MHz, DMSO-d6) d 167.98, 148.40, 148.27, 144.99, 140.14, 130.80, 125.13, 123.46, 121.40, 108.83, 105.99, 101.68. 13 C NMR (62.5 MHz, DMSO-d 6 ) d 167.98, 148.40, 148.27, 144.99, 140.14, 130.80, 125.13, 123.46, 121.40, 108.83, 105.99, 101.68.

실시예Example 3.  3. 피퍼롱구미닌Pepperonguminine (1a)의 제조 Preparation of (1a)

상기 실시예 2에서 얻은 피페린산(6.54 g, 0.3 mol) 및 붕산(Boric acid; 0.02g)을 톨루엔 70 mL 용매에 녹여 얻은 용액을 교반하면서 한꺼번에 이소부틸아민(3.00 g, 0.4 mol)을 적가하였다. 얻어진 혼합물을 16시간 동안 환류하고 약 0.6 mL의 증류수를 딘-스타크 장치(Dean-Stark trap)에서 회수하였다. 이 혼합물을 실온으로 냉각하고 500 mL 헥산을 가하여 즉각적으로 침전이 생성하게 하였다. 추가적으로 30분간 교반을 유지하였으며 침전물을 10% 수성 메탄올로 재결정하여 정제하여 하기 물성치를 갖는 연황색 미세 침상 결정의 피퍼롱구미닌(piperlonguminine) 7.45g (91%)를 수득하였다. Isobutylamine (3.00 g, 0.4 mol) was added dropwise while stirring the solution obtained by dissolving pipelinic acid (6.54 g, 0.3 mol) and boric acid (Boric acid; 0.02 g) obtained in Example 2 in 70 mL of toluene. It was. The resulting mixture was refluxed for 16 hours and about 0.6 mL of distilled water was recovered in a Dean-Stark trap. The mixture was cooled to room temperature and 500 mL hexane was added to cause an immediate precipitate. Further stirring was maintained for 30 minutes and the precipitate was recrystallized with 10% aqueous methanol to obtain 7.45 g (91%) of piperlonguminine of light yellow fine acicular crystals having the following physical properties.

융점 (mp): 166-168℃ (문헌치; 166-168℃)       Melting point (mp): 166-168 ° C. (literature; 166-168 ° C.)

1H NMR (250 MHz, DMSO-d6) δ 0.84 (d, 6H, J = 6.6 Hz), 1.69 (heptet, 1H), 2.95 (t, 2H, J = 6.0 Hz), 6.03 (s, 2H, -OCH2O-,), 6.10 (d, 1H, J = 15.0 Hz, H2), 6.79-6.99 (m, 4H), 7.12 (dd, 1H, J = 15.0, 9.5 Hz, H3). 8.03 (t, J = 6.7 Hz, NH); 1 H NMR (250 MHz, DMSO-d 6 ) δ 0.84 (d, 6H, J = 6.6 Hz), 1.69 (heptet, 1H), 2.95 (t, 2H, J = 6.0 Hz), 6.03 (s, 2H, -OCH 2 0-,), 6.10 (d, 1H, J = 15.0 Hz, H 2), 6.79-6.99 (m, 4H), 7.12 (dd, 1H, J = 15.0, 9.5 Hz, H 3). 8.03 (t, J = 6.7 Hz, NH);

13C NMR (62.5 MHz, DMSO-d6) δ 165.36, 148.13, 147.88, 139.37, 1137.94, 131.09, 125.48, 124.89, 122.85, 108.65, 105.81, 101.46, 46.39, 28.37, 20.41; 13 C NMR (62.5 MHz, DMSO-d 6 ) δ 165.36, 148.13, 147.88, 139.37, 1137.94, 131.09, 125.48, 124.89, 122.85, 108.65, 105.81, 101.46, 46.39, 28.37, 20.41;

고해상 MS (High resolution mass): 273.33.        High resolution mass (MS): 273.33.

본 발명의 미백제로 유용한 피퍼롱구민 화합물을 제조하는 신규 제조방법은 종래기술상의 문제점인 고비용 및 소량 생산 등의 단점을 개선하여 목적물질을 고수율 및 저비용으로 대량 생산이 가능하도록 제조방법이다.The novel production method for preparing the piperlongumin compound useful as a whitening agent of the present invention is a manufacturing method to enable mass production of the target material in high yield and low cost by improving disadvantages such as high cost and small amount production, which are problems in the prior art.

Claims (4)

하기 피페로날(2)을 에틸(E)-4-디에틸포스포노-2-부테노에이트(3)에 NaH를 처리하여 와드워스-호너의 개량된 위티그 축합반응을 수행하여 에틸 피페레이트(4)를 제조하는 제 1단계; 에틸 피페레이트(4)를 메탄올성 KOH하에 가수분해시켜 피페린 산(5)을 얻는 제 2단계; 상기 2단계의 피페린산(5)을 보론산 존재하에서 이소부틸아민과 반응시킴으로서 피퍼롱구미닌 화합물(1a)을 수득하는 제조방법:The following piperonal (2) was treated with NaH in ethyl (E) -4-diethylphosphono-2-butenoate (3) to carry out an improved Wittig condensation reaction of the Wadworth-Honner to ethyl piperate. A first step of manufacturing (4); A second step of hydrolyzing ethyl piperate (4) under methanolic KOH to give piperic acid (5); A method for producing a piperlonguminine compound (1a) by reacting piperinic acid (5) in the second step with isobutylamine in the presence of boronic acid:
Figure 112006087678387-pat00013
Figure 112006087678387-pat00014
Figure 112006087678387-pat00013
Figure 112006087678387-pat00014
Figure 112006087678387-pat00015
Figure 112006087678387-pat00015
Figure 112006087678387-pat00016
Figure 112006087678387-pat00016
Figure 112006087678387-pat00017
Figure 112006087678387-pat00017
삭제delete 하기 알데히드(7)를 트리페닐피페로닐 포스포늄 할로겐화물(8)을 반응시켜 에틸 피페레이트(4)를 제조하는 제1단계; 에틸 피페레이트(4)를 메탄올성 KOH하에 가수분해시켜 피페린 산(5)을 얻는 제 2단계; 상기 2단계의 피페린산(5)을 보론산 존재하에서 이소부틸아민과 반응시킴으로서 피퍼롱구미닌 화합물(1a)을 수득하는 제조방법:A first step of reacting the following aldehyde (7) with triphenylpiperonyl phosphonium halide (8) to produce ethyl piperate (4); A second step of hydrolyzing ethyl piperate (4) under methanolic KOH to give piperic acid (5); A method for producing a piperlonguminine compound (1a) by reacting piperinic acid (5) in the second step with isobutylamine in the presence of boronic acid:
Figure 112006087678387-pat00018
Figure 112006087678387-pat00018
Figure 112006087678387-pat00019
Figure 112006087678387-pat00019
Figure 112006087678387-pat00020
Figure 112006087678387-pat00020
Figure 112006087678387-pat00021
Figure 112006087678387-pat00021
Figure 112006087678387-pat00022
Figure 112006087678387-pat00022
삭제delete
KR1020050073630A 2005-08-11 2005-08-11 Novel preparation method for preparing piperlonguminine compound having skin whitening activity KR100675619B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020050073630A KR100675619B1 (en) 2005-08-11 2005-08-11 Novel preparation method for preparing piperlonguminine compound having skin whitening activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020050073630A KR100675619B1 (en) 2005-08-11 2005-08-11 Novel preparation method for preparing piperlonguminine compound having skin whitening activity

Publications (1)

Publication Number Publication Date
KR100675619B1 true KR100675619B1 (en) 2007-01-30

Family

ID=38015125

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020050073630A KR100675619B1 (en) 2005-08-11 2005-08-11 Novel preparation method for preparing piperlonguminine compound having skin whitening activity

Country Status (1)

Country Link
KR (1) KR100675619B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101209246B1 (en) * 2009-02-02 2012-12-06 주식회사 휴메딕스 Method of manufacturing piperlonguminine
US10071989B2 (en) 2011-06-27 2018-09-11 Tasly Pharmaceutical Group Co., Ltd. Substituted cinnamamide derivative, preparation method and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060036598A (en) * 2004-10-26 2006-05-02 영남대학교 산학협력단 Skin whitening cosmetic composition comprising piperlonguminine compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060036598A (en) * 2004-10-26 2006-05-02 영남대학교 산학협력단 Skin whitening cosmetic composition comprising piperlonguminine compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
논문

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101209246B1 (en) * 2009-02-02 2012-12-06 주식회사 휴메딕스 Method of manufacturing piperlonguminine
US10071989B2 (en) 2011-06-27 2018-09-11 Tasly Pharmaceutical Group Co., Ltd. Substituted cinnamamide derivative, preparation method and use thereof

Similar Documents

Publication Publication Date Title
Chen et al. Synthesis and anti-inflammatory activity of resveratrol analogs
KR101008364B1 (en) Process for preparing racemic or optically pure S-oxiracetam
KATO et al. Prostanoids and related compounds. VI. Synthesis of isoindolinone derivatives possessing inhibitory activity for thromboxane A2 analog (U-46619)-induced vasoconstriction
KR100675619B1 (en) Novel preparation method for preparing piperlonguminine compound having skin whitening activity
JPS62187440A (en) Manufacture of 4-aminohex-5-enoic acid
JPH03109384A (en) Production of (s)-4-hydroxymethyl-gamma-lactone
US5006663A (en) Phosphorus-containing cyclic nitroxide free radicals
JP5648693B2 (en) Manufacturing method of sunsholes
JP5408822B2 (en) 5,6,7,8-Tetra-substituted-1,4-dialkoxy-5,8-epoxy-2,3-dicyano-5,8-dihydronaphthalene derivative and method for producing the same
Thorat et al. Wittig reaction approach for the synthesis of 7-methoxy-2-[4-alkyl/aryl]-l-benzofuran-5-carboxaldehyde
CN1310920C (en) Prepn of racemized and optically active poon essence A and its analog
Sumalatha et al. Synthesis and spectral characterization of process-related substances to the hypnotic agent zolpidem
KR101209246B1 (en) Method of manufacturing piperlonguminine
JPH03153680A (en) Biphenyl compound and its preparation
KR101087500B1 (en) Method for preparing binaphthol aldehyde derivatives and intermediate thereof
JP6984819B2 (en) Zernbon-inducing compounds and cancer cell growth inhibitors and methods for producing them
JP2005350479A (en) Zinc(ii) porphyrin derivative
RU1327491C (en) Composition rossessing antiviral action
Dikusar et al. Methyl-and ethyl carbonates derived from vanillin and vanillal in the synthesis of nitrogen-containing compounds
JP3953141B2 (en) Process for producing 5-methyl-1,4-benzodioxan-6-carboxylic acids and novel intermediates thereof
JPH01143869A (en) Tetrahydrofuranylpyrimidine derivative
JPS6051465B2 (en) 3-Methyl-3-[4-(1-oxo-2-isoindolinyl)phenyl]pyruvic acid esters
KR20100039114A (en) Method for preparing binaphthol aldehyde derivatives and intermediate thereof
CN116621765A (en) Synthesis method and application of 2-indolone analogue containing alpha, beta-unsaturated ketone
RO135588A2 (en) Beta -ketophosphonates with a functionalized pentalenofuran fragment for preparing novel prostaglandin analogues

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130107

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20140106

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20150120

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20170223

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20171117

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20190723

Year of fee payment: 13